Quarterly report pursuant to Section 13 or 15(d)

Financial instruments (Details)

v3.10.0.1
Financial instruments (Details) - 9 months ended Sep. 30, 2018
USD ($)
item
shares
$ / shares
USD ($)
$ / shares
Financial Instruments      
Cash, insured amount     $ 700,000
Sales agreement maximum sales proceeds of stock issuance and sales $ 10,000,000    
Common shares issued for cash, net of issue costs (in shares) | shares 1,536,169    
Common shares issued value $ 7,443,000    
Stock issuance costs 857,000    
Share Price | (per share)   $ 1.05 $ 0.76
Proceeds from shares issued $ 1,100,000    
Sensitivity Analysis Of Fair Value Of Interests Continued To Be Held By Transferor Servicing Assets Or Liabilities Change In Basis Points | item 100    
Credit Concentration Risk      
Financial Instruments      
Cash, uninsured amount     $ 18,400,000
Credit Availability Concentration Risk      
Financial Instruments      
Accounts Payable, Trade, Current     $ 1,000,000
Minimum      
Financial Instruments      
Financial Liabilities Trade Terms Period 30 days    
Minimum | Credit Availability Concentration Risk      
Financial Instruments      
Debt Instrument, Term 3 years    
Maximum      
Financial Instruments      
Financial Liabilities Trade Terms Period 60 days    
Capital Stock      
Financial Instruments      
Common shares issued for cash, net of issue costs (in shares) | shares 12,195,122    
Common shares issued value $ 7,443,000